
sourcing the best research evidence in ophthalmology
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure (MERCURY)
November 1, 2019
Clinical trial
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, Heah T.
Main finding: Netarsudil/latanoprost fixed dose combination (FDC) was superior to netarsudil or latanoprost in lowering intraocular pressure over 3 months.
- Purpose: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost in Ocular Hypertension/Open-angle glaucoma
- Study type: Randomized controlled trial
- Condition: Open angle glaucoma, Ocular Hypertension
Participants: OHT or OAG, unmedicated IOP 21-35 mmHg
- n=718 (MERCURY-1)
Intervention:
- Group 1: Netarsudil 0.02%
- Group 2: Latanoprost 0.005%
- Group 3: Netarsudil/latanoprost fixed dose combination (FDC)
Netarsudil/latanoprost FDC was superior to netarsudil or latanoprost, lowering IOP by an additional 2.2-3.3 mmHg versus netarsudil and an additional 1.5-2.4 mmHg versus latanoprost.
The commonest adverse effect was conjunctival hyperaemia.
Study | Netarsudil | Latanoprost | Netarsudil/latanoprost FDC | |
---|---|---|---|---|
Mean diurnal IOP ≤ 15 mmHg (proportion) | MERCURY-1 | 15.8% | 18.3% | 42.1% |
MERCURY-2 | 22.7% | 24.7% | 43.5% | |
Incidence of Conjunctival hyperaemia | MERCURY-1 and 2 | 41-42.7% | 14-22.3% | 53.4-54.5% |
September 1, 2019
Clinical trial
Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
Walters TR, Ahmed IIK, Lewis RA, Usner DW, Lopez J, Kopczynski CC, Heah T.
Main finding: Netarsudil/latanoprost fixed dose combination (FDC) was superior to netarsudil or latanoprost in lowering intraocular pressure over 3 months.
- Purpose: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost in Ocular Hypertension/Open-angle glaucoma
- Study type: Randomized controlled trial
- Condition: Open angle glaucoma, Ocular Hypertension
Participants: OHT or OAG, unmedicated IOP 21-35 mmHg
- n=750 (MERCURY-2)
Intervention:
- Group 1: Netarsudil 0.02%
- Group 2: Latanoprost 0.005%
- Group 3: Netarsudil/latanoprost fixed dose combination (FDC)
Netarsudil/latanoprost FDC was superior to netarsudil or latanoprost, lowering IOP by an additional 2.2-3.3 mmHg versus netarsudil and an additional 1.5-2.4 mmHg versus latanoprost.
The commonest adverse effect was conjunctival hyperaemia.
Study | Netarsudil | Latanoprost | Netarsudil/latanoprost FDC | |
---|---|---|---|---|
Mean diurnal IOP ≤ 15 mmHg (proportion) | MERCURY-1 | 15.8% | 18.3% | 42.1% |
MERCURY-2 | 22.7% | 24.7% | 43.5% | |
Incidence of Conjunctival hyperaemia | MERCURY-1 and 2 | 41-42.7% | 14-22.3% | 53.4-54.5% |
Source Archive